Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Riitta, Luosujärvi"'
Autor:
Tuija Väänänen, Katriina Vuolteenaho, Hannu Kautiainen, Riina Nieminen, Timo Möttönen, Pekka Hannonen, Markku Korpela, Markku J Kauppi, Kari Laiho, Oili Kaipiainen-Seppänen, Riitta Luosujärvi, Tea Uusitalo, Toini Uutela, Marjatta Leirisalo-Repo, Eeva Moilanen, NEO-RACo Study Group
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183294 (2017)
YKL-40, a chitinase-like glycoprotein associated with inflammation and tissue remodeling, is produced by joint tissues and recognized as a candidate auto-antigen in rheumatoid arthritis (RA). In the present study, we investigated YKL-40 as a potentia
Externí odkaz:
https://doaj.org/article/6049803f74e6424a87fd85ebba81496f
Autor:
Hanna Säilä, Kristiina Aalto, Hannu Kautiainen, L Ristolainen, T Orenius, Riitta Luosujärvi, K Rebane, Heikki Relas
Publikováno v:
Scandinavian Journal of Rheumatology. 48:408-414
Objective: Pain is a common and distressing feature of juvenile idiopathic arthritis (JIA). Pain interference (PI) is underexplored in long-term conditions such as JIA. The aim of this study was to...
Publikováno v:
Modern Rheumatology. 28:832-837
Objectives: Across diagnosis groups, successful transition of adolescent and young adults from children's hospitals to adult care is often associated with decreased treatment adherence and treatment results. The aim of this study was to characterize
Publikováno v:
Advances in Therapy
Purpose To model the American College of Rheumatology (ACR) outcomes, cost-effectiveness, and budget impact of certolizumab pegol (CZP) (with and without a hypothetical risk-sharing scheme at treatment initiation for biologic-naïve patients) versus
Autor:
Hannu Kautiainen, L Ristolainen, Hanna Säilä, Kristiina Aalto, Riitta Luosujärvi, Heikki Relas, K Rebane, T Orenius
Publikováno v:
Scandinavian journal of rheumatology. 48(2)
To describe a cohort of Finnish juvenile idiopathic arthritis (JIA) patients, to recognize those young adults who are at risk of becoming socially restricted by their long-term rheumatic disease, and to assess which areas of self-rated health-related
Autor:
T. Valiviita, S. Lindqvist, Kirsi Taimen, Laura Pirilä, Riitta Luosujärvi, R. Roiha, Kari K. Eklund, P. Isomäki, Oili Kaipiainen-Seppänen, Anna Karjalainen, S. Viinikainen, S. Arvonen, Heidi Mäkinen
Publikováno v:
Public health, health services research and health economics.
Background Finnish on-line Health village environment, so-called HUS-MAP©, was used to develop on-line information for rheumatic patients. Objectives To face the challenge of increasing demand for rheumatological care without additional resources a
Autor:
Riitta Luosujärvi, T Orenius, Säilä H, K Rebane, Kristiina Aalto, Hannu Kautiainen, Heikki Relas, L Ristolainen
Publikováno v:
THURSDAY, 14 JUNE 2018.
Background Pain is one of the most distressing and persisting features of JIA and frequently interferes with everyday life. Objectives This study was conducted to find out the factors associated with pain interference in young adults (aged 18 to 30 y
Autor:
Säilä H, Riitta Luosujärvi, L Ristolainen, T Orenius, K Rebane, Heikki Relas, Hannu Kautiainen, Kristiina Aalto
Publikováno v:
Poster Presentations.
Background Health related quality of life of adult patients with juvenile idiopathic arthritis (JIA) is shown to be significantly lower compared to the general population.1,2 Objectives We aimed to recognize young adults with JIA who are socioeconomi
Autor:
K-L Vidqvist, A Häme, A Puhakka, P. Parmanne, Ritva Peltomaa, Heidi Mäkinen, J Panelius, T Hasan, M Perovaara, Riitta Luosujärvi
Publikováno v:
Abstracts Accepted for Publication.
Background Raynaud9n phenomenon (RP) is very common all around the world, especially in cold climates (from 3 to 22%) (1). Nailfold capillaroscopy and autoantibodies have a pivotal role in diagnosing of different diseases in the context of RP (2).Thi
Autor:
Veli-Jukka, Anttila, Johanna, Haapamäki, Ritva, Peltomaa, Tarja, Tiippana-Kinnunen, Riitta, Luosujärvi
Publikováno v:
Duodecim; laaketieteellinen aikakauskirja. 132(4)
The use of biological drugs in the treatment of inflammatory rheumatic diseases, bowel diseases, and psoriasis has increased. Patients receiving a biological drug are invariably under the supervision of a specialized physician, but many are also atte